Ulcerative Colitis

More patients also achieved endoscopic and histologic remission in the treatment group compared to the placebo group.

The findings should assuage concerns about small intestinal bacterial overgrowth when prescribing treatment with proton pump inhibitors.

In the U-ACCOMPLISH study, 37% of patients treated with upadacitinib achieved histologic-endoscopic mucosal improvement at week 8.

Crohn’s disease patients and ulcerative colitis patients showed changes in energetic metabolism in plasma and biopsy samples compared to a control group.

Todd Schlesinger, MD, talks new therapies on the horizon and those that have already proven efficacious.

A related editorial noted the study authors’ numbers were higher than those of the Mayo Clinic.

About half of patients experienced adverse events, and two-thirds of those events were likely related to inflammatory bowel disease medications.

Approximately 30% of patients treated with upadacitinib achieved endoscopic mucosal improvement at week 8, compared to just 7% of the placebo group

This combination therapy may have a few advantages over standard corticosteroid regimens.

Despite the difficult circumstances, experts believe colorectal cancer rates will not decrease in the coming years due to delays in screenings.

The top-line results from the ABX464 study conducted in 15 European countries, as well as the US and Canada, are expected during the second quarter of 2021.

Inflammatory bowel disease patients were surveyed about their remission or flare-up status, as well as their expectations for a flare-up over the next 2 months.

Life expectancy rates were lower in patients with IBD when compared to a healthy control group.

Female gender, Caucasian race, and older age were all significantly associated with microscopic colitis.

Tunneled catheters resulted in lower rates of deep vein thrombosis when compared to PICCs.

Over the course of the 19 year review, biologic use has increased, while the prevalence of colectomies has decreased.

A new study demonstrates that vedolizumab is associated with real-world corticosteroid-free response and remission in patients with ulcerative colitis and Crohn’s disease.

Anti-TNFs, vedolizumab, ustekinumab, thiopurines, and 5-ASA were all linked to a lower risk of myocardial infarctions.

A poster presented at ACG provides an updated analysis of clostridium difficile infection in the tofacitinib UC clinical program.

Researchers test 3 different doses of mirikizumab in both biologic experienced and naïve Crohn’s disease patients.

Ustekinumab resulted in a reduction of both stool frequency and rectal bleeding for ulcerative colitis patients.

More than half of the patient population achieved a defined response at both day 14 and week 6.

A new study presented at ACG shows vedolizumab to be superior to adalimumab in maintaining early disease control in patients with moderate-to-severe ulcerative colitis.

In a poster presented during ACG, investigators show data from a long-term extension of the UNIFI trial.

Investigators compared 2 groups, before and after the initiation of a biosimilar program at their hospital.